Germany

Germany's health product regulatory landscape is governed by a dual-authority structure. The Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) oversees pharmaceuticals, medical devices, diagnostics, and digital health applications, while the Paul-Ehrlich-Institut (PEI) holds authority over biological medicines including vaccines, blood products, and advanced therapy medicinal products (ATMPs). The overarching legislative framework includes the Arzneimittelgesetz (AMG, Medicines Act), the Medizinprodukterecht-Durchführungsgesetz (MPDG) implementing EU MDR 2017/745 and EU IVDR 2017/746, and the Digitale-Versorgung-Gesetz (DVG) for digital health applications. Germany participates fully in the European Medicines Agency (EMA) centralized procedure for eligible products, and national procedures are conducted in parallel with EU mutual recognition and decentralized processes where applicable.

For pharmaceutical submissions, Germany follows the Common Technical Document (CTD) format in line with ICH guidelines, and dossiers must be submitted through the EudraLink or similar electronic portals. A local European Economic Area (EEA) representative or EU-based marketing authorization holder is required for non-EU manufacturers. Medical devices must bear CE marking under EU MDR or EU IVDR before market placement, with Notified Bodies such as TÜV SÜD or TÜV Rheinland conducting conformity assessments. Digital health applications (Digitale Gesundheitsanwendungen, DiGA) follow a distinct fast-track pathway managed by BfArM, enabling provisional listing within 90 days pending evidence of positive care effects. Notable recent reforms include the full applicability of EU IVDR from May 2022 (with transition extensions), the expansion of the DiGA framework under the Digitale-Versorgung-und-Pflege-Modernisierungs-Gesetz (DVPMG), and Germany's active role in piloting the EU Health Technology Assessment (HTA) Regulation 2021/2282, which became applicable in January 2025 for oncology and ATMPs.

Germany operates a highly decentralized, social insurance-based healthcare procurement system. The statutory health insurance (Gesetzliche Krankenversicherung, GKV) framework covers approximately 90% of the population and is administered through more than 90 competing Krankenkassen (sickness funds) under oversight of the Bundesministerium für Gesundheit (BMG, Federal Ministry of Health). Reimbursement and pricing for pharmaceuticals are governed by the Arzneimittelmarktneuordnungsgesetz (AMNOG) framework, under which all newly approved medicines with claimed added benefit undergo early benefit assessment by the Gemeinsamer Bundesausschuss (G-BA, Federal Joint Committee), followed by price negotiations between manufacturers and the GKV-Spitzenverband (National Association of Statutory Health Insurance Funds). Medical devices and diagnostics are subject to separate reimbursement pathways including the Hilfsmittelverzeichnis (aids and appliances directory) and hospital DRG-based procurement, which is largely managed at the Länder (state) level through individual hospital tenders and group purchasing organizations such as the Einkaufsgemeinschaft GEMED or Sana-Einkauf.

The private healthcare sector in Germany, serving approximately 10% of the population through private health insurance (PKV), operates under independent contractual and pricing arrangements, offering more flexible access for innovative products outside GKV reimbursement constraints. Germany does not rely significantly on multilateral donor procurement channels such as UNICEF Supply Division, the Global Fund, USAID, or Gavi, as it is a high-income donor country rather than a recipient. However, German institutions including GIZ (Deutsche Gesellschaft für Internationale Zusammenarbeit) and KfW Development Bank actively fund and facilitate health procurement in lower-income countries. There is no formal domestic local manufacturing preference policy mandated for standard health procurement; however, the German government has increased strategic focus on supply chain resilience and domestic or EU-based production capacity for critical medicines and medical countermeasures, particularly following COVID-19 supply disruptions and in alignment with the EU Critical Medicines Act and European Health Emergency Preparedness and Response Authority (HERA) initiatives.